Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation

Fig. 4

SRF transcriptional activity was assessed in Ag and PC3 docetaxel resistant (D12) cells which were seeded in 12-well plates at a density of 100,000 cells per well. The following day they were transiently transfected using a dual luciferase assay system, where the reporter construct is driven by SRF and tK renilla responsive elements. Twenty-four hours post-transfection, cells were treated with either 20 nM docetaxel or a similar volume of vehicle control for 6 h. Reporter gene activity was then measured by illuminometry, and relative SRF:tkRenilla transcriptional activity calculated. * = p < 0.05. No statistical difference between SRF transcriptional activity in PC3-Ag cells at baseline vs. treatment with docetaxel was observed (represented by the dashed line). (n = 3.)

Back to article page